GLIOSARCOMA

This study tests a vaccine called SurVaxM, given with standard chemotherapy, for people with a newly diagnosed aggressive brain cancer (glioblastoma). The vaccine is designed to train the immune system to attack cancer cells. The main goal is to see if adding the vaccine helps ke…

This trial tests an implantable ultrasound device that temporarily opens the blood-brain barrier, allowing chemotherapy to reach brain tumors more effectively. It involves 57 patients with recurrent glioblastoma, a fast-growing brain cancer. The goal is to find a safe dose and se…

This study tests whether adding a second chemotherapy drug (lomustine) to the standard treatment (temozolomide plus radiation) helps people with a specific type of glioblastoma, a fast-growing brain cancer. The trial includes 265 adults whose tumors have a genetic marker (MGMT me…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy and radiation can help people with newly diagnosed glioblastoma, an aggressive brain cancer. About 52 adults will receive the combination to see if it improves survival and controls the …

This early-phase trial tests a new drug called selinexor alongside standard radiation and chemotherapy for people with newly diagnosed glioblastoma, an aggressive brain cancer. The main goal is to find the highest safe dose of selinexor that can be given with these treatments. Ab…

This study tests whether adding veliparib to standard chemotherapy (temozolomide) helps people with a newly diagnosed, aggressive brain cancer called glioblastoma. The cancer must have a specific genetic marker (MGMT hypermethylation). About 447 participants will receive either t…

This early study tests whether adding the drug S-Gboxin to standard radiation and chemotherapy can help people with glioblastoma or diffuse midline glioma, two aggressive brain cancers. About 10 participants whose tumors have returned or worsened will receive the combination. The…

This study looks at whether a special MRI scan can measure blood flow changes in brain tumors (glioblastoma) that have come back. The goal is to see if these changes can predict how well the drug bevacizumab is working, just two weeks after starting treatment. About 146 adults wi…